Eisai Company, Limited

Eisai R&d Management Co., Ltd.

Hitachi Power Semiconductor Device, Ltd.

Atsushi Sasaki

Yasuhiro Watanabe

Makoto Komatsu

Daisuke Maeda

Hiroyuki Hasegawa

Atsuhiko Kubota

Noritaka Kitazawa

Tadashi Okabe

Youichi Iimura

Hachiro Sugimoto

Kiyomi Yamatsu

Norio Karibe

Yoshiharu Yamanishi

Hiroo Ogura

Takashi Kosasa

Satoshi Nagato

Koki Kawano

Keiko Takahashi

Kohshi Ueno

Manabu Matsunaga

Masahiro Yonaga

Kumi Uchikoshi

Yuichi Suzuki

Teiji Kimura

Atsushi Kamada

Kazumasa Nara

Noboru Yamamoto

Shinichi Hamaoka

Yutaka Tsuchiya

Kunizou Higurashi

Shin Araki

Michiko Kosasa

Koichi Ito

Akiharu Kajiwara

Kozo Akasaka

Kenji Sakurai

Masanori Mizuno

Ichirou Yoshida

Miyuki Sakai

Mariko Komatsu

Takaki Kagaya

Koshi Ueno

Hiroki Ishihara

Shinichi Tsukuba Res Lab Eisai Co Ltd Hamaoka

Tadashi c/o Tsukuba Research Laboratories Okabe

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Rand Rare the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R&#x2033; represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

Selective estrogen receptor modulator

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like;&#x2003;&#x2003;(I-1)formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Rand Rare the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R&#x2033; represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like;formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Rand Rare the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R&#x2033; represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.

The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein Rand Rare substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; Rrepresents a hydrogen atom or the like; and Rrepresents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.

Indole derivative having piperidine ring

A novel compound of the formula:wherein A, B, C, D, T, Y, and Z represent each methine or nitrogen; RR, R, R, and Rrepresent each a substituent; n represents 0 or an integer of 1 to 3; m represents 0 or an integer of 1 to 6; and p represents an integer of 1 to 3; and pharmacologically acceptable salts thereof. The compound has a serotonin antagonism and is clinically useful as medicament, in particular, for treating, ameliorating and preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

Quinoline derivatives

Condensed pyridine compounds represented by formula (I):wherein: Rand Rare, independently, hydrogen, lower alkyl, or lower alkoxy; Rrepresent an amino substituent; ring A is a benzene ring, pyridine ring, thiophene ring, or furan ring; and B represents a substituent containing a ring structure. Also, pharmaceutically acceptable salt and hydrates thereof. These compounds are clinically useful medicaments having serotonin antagonism, and in particular, for treating, ameliorating, or preventing spastic paralysis. They are also useful as central muscle relaxants for ameliorating myotonia.

Certain 1,3-disubstituted isoquinoline derivatives

Indoles

1,4-substituted cyclic amine derivatives

Fused pyridine derivatives

The cyclic amide derivative is defined by the formula (I) or a salt thereof: R1-(CH2)n-Z in which R1 is a group derived from a cyclic amide compound, substituted or unsubstituted, n is zero or an integer of 1 to 10 and Z is ##STR1## R2 being an aryl, a substituted aryl, a cycloalkyl or a heterocyclic group, m being an integer of 1 to 6, R3 being hydrogen or a lower alkyl, R4 being an aryl or a substituted aryl, a cycloalkyl or a heterocyclic group, p being an integer of 1 to 6, provided that the cyclic amide compound is quinazoline-on or quinazoline-dion, R2 and R4 are neither aryl nor substituted aryl. The cyclic amide compound is pharmacologically effective to prevent and treat diseases due to insufficiency of the central choline functions.

Cyclic amide derivatives

The cyclic amide derivative is defined by the formula (I) or a salt thereof: R.sup.1 --(CH.sub.2)n-Z in which R.sup.1 is a group derived from a cyclic amide compound, substituted or unsubstituted, n is zero or an integer of 1 to 10 and Z is ##STR1## R.sup.2 being an aryl, a substituted aryl, a cycloalkyl or a heterocyclic group, m being an integer of 1 to 6, R.sup.3 being hydrogen or a lower alkyl, R.sup.4 being an aryl or a substituted aryl, a cycloalkyl or a heterocyclic group, p being an integer of 1 to 6, provided that the cyclic amide compound is quinazoline-on or quinazoline-dion, R.sup.2 and R.sup.4 are neither aryl nor substituted aryl. The cyclic amide compound is pharmacologically effective to prevent and treat diseases due to insufficiency of the central choline functions.

Bicyclic amide derivatives, compositions and methods of treatment

The cyclic amide derivative is defined by the formula (I) or a salt thereof: R.sup.1 --(CH2)n--Z in which R.sup.1 is a group derived from a cyclic amide compound, substituted or unsubstituted, n is zero or an integer of 1 to 10 and Z is ##STR1## R.sup.2 being an aryl, a substituted aryl, a cycloalkyl or a heterocyclic group, m being an integer of 1 to 6, R.sup.3 being hydrogen or a lower alkyl, R.sup.4 being an aryl or a substituted aryl, a cycloalkyl or a heterocyclic group, p being an integer of 1 to 6, provided that the cyclic amide compound is quinazoline-on or quinazoline-dion, R2 and R4 are neither aryl nor substituted aryl. The cyclic amide compound is pharmacologically effective to prevent and treat diseases due to insufficiency of the central choline functions.

Benzoxazine derivatives

The cyclic amide derivative is defined by the formula (I) or a salt thereof:

1,2,3,4 tetrahydropteridinone cyclic amide derivatives

2H-3,4-tetrahydroquinazoline-2-one and

Growing community of inventors

Ibaraki, Japan

Atsushi Sasaki